• Solid 2025 financial results
• Integration of CH2, Oborne and ParagonCare progressing well
• New Brisbane warehouse nearly complete
• New business units launched in aesthetics, robotics and dental
• Synergies being achieved as forecast

The Chair's address highlighted Paragon Care's solid financial results in 2025, with the integration of CH2, Oborne and ParagonCare progressing well, though some work remains on IT systems and the Finance function. The new Brisbane warehouse is nearly complete, and new business units focused on aesthetics, robotics and dental were launched across Australia and New Zealand. Synergies are being achieved as forecast, and more efficient financing is in place. The company's Asian businesses performed well, and Paragon Care plans to expand further, including the acquisition of 100% of the Somnotec Group. The Chair acknowledged the contribution of former CEO David Collins and welcomed the new CEO, Carmen Riley. The company is working with Infinity Retail Pharmacy Group on a payment and debt restructure plan. Trading for the first four months of the new financial year has been good, and the CEO will provide more detail on the 2026 outlook and longer-term prospects for Paragon Care.

Trading for the first four months of FY26 has been good. No specific financial metrics provided.

The company plans to expand further in Asia Pacific, including the acquisition of Somnotec Group. The CEO will provide more detail on the 2026 outlook and longer-term prospects for Paragon Care.